Simpler Antithrombotic Regimens Hold Up After LAAC

Simpler Antithrombotic Regimens Hold Up After LAAC

A single, lower-dose antithrombotic was as effective as dual antiplatelet therapy (DAPT) at preventing major adverse outcomes after left atrial appendage closure (LAAC) in patients with atrial fibrillation (AF), results from the randomized controlled SIMPLAAFY trial showed.Compared with a full 6 months of DAPT after the procedure, the composite risk for all-cause death, stroke, systemic embolism, and major bleeding was noninferior for aspirin whether given alone for a planned 12 months or after 3 months of a reduced-dose non-vitamin K oral anticoagulant (NOAC).Major bleeding as a safety endpoint was substantially reduced with the less intensive regimens as well.Researchers said the results support simplifying post-LAAC antithrombotic care, with the choice between aspirin alone and a short course of reduced-dose NOAC tailored to each patient’s bleeding and clot risk.“We’ve been slowly reducing the amount of medications that people have to take after they undergo the WATCHMAN FLEX procedure,” investigator Megan Coylewright, MD, structural interventional cardiologist with Essentia Health in Duluth, Minnesota, told Medscape Medical News. “What we are learning is that we don’t need as much blood thinner in that healing stage as we thought.”The study was published online on November 2 in JAMA.Simplifying LAACLAAC with the WATCHMAN device typically includes antithrombotic treatment to avoid device-related thrombus in the early postimplant period during healing and endothelialization of the device. As a recent review in JACC noted, a NOAC plus aspirin followed by DAPT has been increasingly used for that purpose, whereas oral anticoagulation alone and DAPT alone are also common.SIMPLAAFY is one of several ongoing and recently initiated trials testing whether antithrombotic therapy after LAAC can be safely simplified, including strategies of no therapy.It’s a scenario playing out across interventional cardiology, Coylewright said.“As technology continues to improve, the risk of clots forming on devices of all kinds is really falling,” she said. “So if we don’t have that high of a risk of clot, then we don’t need that much blood thinner to prevent it, and therefore, patients are exposed to much less bleeding risk.”Her group conducted SIMPLAAFY as an open-label clinical trial at 87 US investigational sites. It included 1857 patients with nonvalvular AF (62.2% aged ≥ 75 years; 42.9% women) who had a successful LAAC procedure with a WATCHMAN FLX Pro device between October 2024 and December 2025 and were eligible for all three tested regimens.Patients were excluded from enrollment for reasons including residual peridevice leak at the time of implant, a periprocedural complication before randomization, a recent cerebrovascular or cardiovascular event or major bleeding, or a need for long-term anticoagulation outside of AF stroke prevention.Participants were equally and randomly assigned to DAPT (75 mg clopidogrel plus 81-100 mg aspirin per day) for 6 months followed by aspirin; a reduced-dose NOAC (preferentially 2.5 mg apixaban twice daily or 10 mg rivaroxaban daily) for 3 months followed by aspirin; or 81-100 mg aspirin per day alone for 12 months.The CHA2DS2-VASc stroke risk score averaged 4.2, and the HAS-BLED bleeding risk score averaged 2.6.A ‘Bleeding Penalty’The primary outcome — the 6-month composite of all-cause death, stroke, systemic embolism, or major bleeding — occurred in 6.9% of patients on DAPT, 5.1% on reduced-dose NOACs, and 3.3% on aspirin alone.Compared with DAPT, the 1.7-percentage-point absolute difference with reduced-dose NOACs was not statistically significant (risk ratio, 0.75; 95% CI, 0.48-1.18) but fell well within the prespecified noninferiority margin of 7.2 percentage points (97.5% upper bound, 1.2).Aspirin alone offered better outcomes. The 3.5-percentage point difference favored aspirin monotherapy compared with DAPT (risk ratio, 0.49; 95% CI, 0.29-0.82). Aspirin also met noninferiority (97.5% upper bound, -0.8; P < .001).Major bleeding was the largest contributor to the primary endpoint, with rates of 4.5% with DAPT, 2.7% with reduced-dose NOACs, and 1.7% with aspirin alone. Clinically relevant nonmajor bleeding showed a similar pattern (8.7%, 4.8%, and 3.8%, respectively).Device-related thrombus occurred in 3.4%, 0.9%, and 2.7% across those groups, respectively.“The current trial provides more precise randomized evidence that DAPT is not required to preserve short-term clinical outcomes and instead imposes a bleeding penalty,” the researchers wrote.“These findings support the simplification of post-LAAC antithrombotic management after uncomplicated device implantation and suggest that selection between monotherapy strategies may be individualized according to competing bleeding and device-thrombosis risks and patient preferences,” they continued.Challenging AssumptionsCommenting on the findings for Medscape Medical News, Aakriti Gupta, MD, MSc, assistant professor of cardiology at Cedars-Sinai in Los Angeles, said that while the results show the appeal of reduced-dose NOACs, “they do not establish a definitive preferred regimen.”Also, only four ischemic strokes occurred in each group, “so the study provides limited precision about differences in stroke prevention itself,” added Gupta, investigator of the JACC review on LAAC management who was not part of the current trial.“SIMPLAAFY challenges the assumption that dual antiplatelet therapy is the gentler option after LAAC. The findings support simpler treatment for selected patients while leaving an important question open: whether the early bleeding benefit is accompanied by durable protection from clots and stroke,” Gupta said.“Simplifying postimplant treatment could meaningfully improve patient outcomes, but the trial does not establish that the population offered LAAC should itself be expanded,” she added.A Case for Market Expansion?The trial was designed by the device manufacturer Boston Scientific Corporation in conjunction with the FDA to support market expansion of the antithrombotic regimen after implantation.Gupta said she thought the trial “provides a reasonable basis for considering expanded postimplant antithrombotic options in carefully selected patients after uncomplicated WATCHMAN FLX Pro implantation.”While the 6-month study duration was meaningful, Gupta called for longer follow-up to establish the durability of that safety.“Later imaging will matter because this report includes imaging results only at 45 days; the planned 12-month assessment is still pending,” she said.Coylewright said she couldn’t speculate on what the FDA would decide but that the 6-month data were enough from a clinician perspective to affect practice.“We really worry about the risk of device-related thrombus and bleeding in the first 3 months after we put in the device, and this study is very reassuring that we can reduce the severity of the blood thinners we’re using after WATCHMAN,” she said. “We can do that right away based on the data.”In an editorial accompanying the JAMA paper, James V. Freeman, MD, MPH, professor of cardiovascular medicine at Yale University School of Medicine in New Haven, Connecticut, agreed.“These findings are entirely consistent with other large registry and trial results, and hopefully real-world practice patterns will shift accordingly,” Freeman wrote.While the “substantially higher rates of bleeding and device-related thrombus with DAPT suggests that this was the least favorable treatment strategy in this trial population,” the study was neither powered for those secondary endpoints nor had adjustment for multiple comparisons, Freeman cautioned.Other limitations included an unblinded design that allowed for potential bias in assessment, the lack of a full-dose NOAC group (the default antithrombotic regimen used by many physicians), and the lack of patients with an absolute contraindication to even short-term anticoagulation.The SIMPLAAFY trial was sponsored and funded by Boston Scientific. Disclosures for study and editorial authors can be found in the original articles. Gupta disclosed research funding from the National Institutes of Health and the Patient-Centered Outcomes Research Institute; equity in iCardio.ai, Heartbeat Health, and AllHeart; and an honorarium from Edwards Lifesciences.

Original Source

Read the full article at Medscape →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.